Clinical trials: Schizo-Affective Disorder
Schizophrenia, Schizoaffective Disorder
Evaluation of mHealth for Serious Mental Illness
This study is a waitlist control trial evaluating the acceptability and preliminary efficacy of a smartphone application with people with mental illness.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT04068467
- Testing
- Smartphone App, Waitlist Control
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- University of Washington
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, psychotic symptoms and social functioning in schizophrenia.
- Trial name
- OTS-12WK (NCT01394471)
- Testing
- Intranasal Oxytocin Spray
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- TrypNAC-II (NCT04013555)
- Testing
- N-acetylcysteine (NAC), Tryptophan
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Maryland, Baltimore
Healthy
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.
- Trial name
- NCT00581243
- Testing
- SLV-313 SR
- Volunteers
- 32 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Clinical Trial of AVL-3288 in Schizophrenia Patients
Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients…
- Trial name
- NCT02978599
- Testing
- AVL-3288
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Study by Electroencephalography of the Link Between the Lack of Self-compassion and the Disorder of Empathy in Schizophrenia
This research project focuses on a fundamental element of the psychopathology of schizophrenia, that is to say, the disorders of self-awareness and on the functional alterations associated with it, that is to say, self-compassion…
- Trial name
- SCE-SCHIZO (NCT05464563)
- Testing
- Electroencephalogram
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Henri Laborit
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizo Affective Disorder
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- INITIATE (NCT04907279)
- Testing
- Aripiprazole Once-Monthly (AOM)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Schizophrenia, Schizoaffective Disorder
Comparing Cognitive Remediation Approaches for Schizophrenia
This research compares the relative efficacy of two empirically-supported, standardized programs of cognitive remediation for treatment of cognitive deficits and community function in schizophrenia to help inform best practices.
- Trial name
- NCT04123223
- Testing
- Cognitive Remediation, Computer Games
- Where
- 2 sites in United States
- Volunteers
- 135 people
- Sponsor
- Wesleyan University
Mental Illness Persistent, Cardiovascular Prevention
Cardiac Rehabilitation for Cardiovascular Risk Reduction in People With Severe and Persistent Mental Illness
The goal of this prospective, randomized trial is to explore the link between cardiovascular disease and mortality in individuals with severe and persistent mental illness (SPMI).
- Trial name
- NCT05659498
- Testing
- Cardiac Rehabilitation Program
- Where
- Canada
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Lady Davis Institute
Borderline Personality Disorder, BPD
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Social cognition impairment is critical to the pathology and morbidity of a number of psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and the personality disorders, thus representing a dimension…
- Conditions
- Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD
- Trial name
- NCT02149823
- Testing
- Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU)
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Maria de las Mercedes Perez Rodriguez
Schizophenia Disorder, Major Depression Disorders
Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment
The goal of this clinical trial is to find if patients would awaken quickly after electroconvulsive treatment when remimazolam is used compared to etomidate. It will also learn about the efficacy of remimazolam.
- Conditions
- Schizophenia Disorder, Major Depression Disorders, Schizoaffective Disorder, Bipolar
- Trial name
- NCT06664138
- Testing
- Remimazolam, Etomidate
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yeongseok Yun
Schizophrenia, Schizoaffective Disorder
Health Evaluation of Abilify Long-term Therapy
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment.
- Trial name
- HEALTH (NCT00520650)
- Testing
- Aripiprazole
- Where
- 9 sites in Taiwan
- Volunteers
- 245 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Schizophrenia, Schizoaffective Disorder
Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia
Many individuals with schizophrenia continue to hear voices, have false beliefs, and problems with attention, memory planning and everyday functioning even with medication treatment.
- Trial name
- Mcog (NCT01915017)
- Testing
- Cognitive Behavior Therapy for Psychosis, Cognitive Adaptation Training, Multi-modal Cognitive Therapy
- Volunteers
- 178 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients
The purpose of this study was to evaluate the safety of risperidone treatment in acute psychotic patients that require an admission into emergency department.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00515489
- Testing
- Risperidone
- Volunteers
- 1,882 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizoaffective Disorder
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
- Trial name
- NCT01242371
- Testing
- Probiotic Supplement
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia, Schizoaffective Disorder
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing…
- Trial name
- NCT00237809
- Testing
- D-serine, Cognitive Retraining (CRT)
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Neurophysiological Studies in Schizophrenia and Psychiatric Disorders
The overall goal of this project is to identify intermediate phenotypes for psychosis across the schizophrenia and bipolar disorders boundary with implications for future genetic studies.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- BSNIP (NCT01384604)
- Where
- United States
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center